Conditions: Alzheimer Disease
Keywords: antibody immunotherapy
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 901
Healthy volunteers: no

Brief summary:
This is a study to evaluate the efficacy and safety of multiple doses of bapineuzumab in patients with mild to moderate Alzheimer Disease. Patients will receive either bapineuzumab or placebo. Each patient's participation will last approximately 1.5 years.

Detailed description:

Arms:
arm 1: None arm 2: None arm 3: None

Interventions: intervention 1: bapineuzumab intervention 2: bapineuzumab intervention 3: placebo
Intervention descriptions: intervention 1: Bapineuzumab 0.5 mg/kg administered by IV infusion approximately every 13 weeks through week 65. intervention 2: Bapineuzumab 1.0 mg/kg administered by IV infusion approximately every 13 weeks through week 65. intervention 3: Placebo will be administered by IV infusion approximately every 13 weeks through week 65.

Protocol document: